| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8443913 | European Journal of Cancer | 2013 | 7 Pages |
Abstract
This trial demonstrated no survival benefit of the addition of dose dense temozolomide, to standard radiotherapy in children with classical DIPG. However, a subgroup of adolescent DIPG patients did have a prolonged survival, which needs further exploration.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
S. Bailey, A. Howman, K. Wheatley, D. Wherton, N. Boota, B. Pizer, D. Fisher, P. Kearns, S. Picton, F. Saran, M. Gibson, A. Glaser, D.J.A. Connolly, D. Hargrave,